Rheumatology Oxford Journal
Fecha de publicación: 20 January 2020
DOI: https://doi.org/10.1093/rheumatology/kez683
Autores: Gabriele Simonini, Athimalaipet V Ramanan
Background: The standard of care for the management of children with JIA has moved towards a step-by-step escalation, with early immunosuppressive therapy to achieve remission. Biologics have markedly improved disease control in JIA, and in many centres anti-TNF-α therapies represent the first-line treatment in children refractory to MTX.
Leer más
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.